» Articles » PMID: 19955655

TGF-beta1-induced Expression of Human Mdm2 Correlates with Late-stage Metastatic Breast Cancer

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2009 Dec 4
PMID 19955655
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%-80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-beta1. Whether TGF-beta1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-beta1-activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-beta1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-beta1-mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-beta1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.

Citing Articles

Non-small cell lung cancer map and analysis: exploring interconnected oncogenic signal integrators.

Gottumukkala S, Palanisamy A Mamm Genome. 2025; .

PMID: 39939487 DOI: 10.1007/s00335-025-10110-6.


Induction of the Mdm2 gene and protein by kinase signaling pathways is repressed by the pVHL tumor suppressor.

Mabry A, Singh A, Mulrooney B, Gorman J, Thielbar A, Wolf E Proc Natl Acad Sci U S A. 2024; 121(31):e2400935121.

PMID: 39047034 PMC: 11295014. DOI: 10.1073/pnas.2400935121.


Comprehensive molecular interaction map of TGFβ induced epithelial to mesenchymal transition in breast cancer.

Gottumukkala S, Ganesan T, Palanisamy A NPJ Syst Biol Appl. 2024; 10(1):53.

PMID: 38760412 PMC: 11101644. DOI: 10.1038/s41540-024-00378-w.


MDM2: current research status and prospects of tumor treatment.

Yao Y, Zhang Q, Li Z, Zhang H Cancer Cell Int. 2024; 24(1):170.

PMID: 38741108 PMC: 11092046. DOI: 10.1186/s12935-024-03356-8.


Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer.

Li H, Shi W, Shen T, Hui S, Hou M, Wei Z Medicine (Baltimore). 2023; 102(41):e35384.

PMID: 37832105 PMC: 10578738. DOI: 10.1097/MD.0000000000035384.


References
1.
Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

2.
Montes de Oca Luna R, Wagner D, Lozano G . Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995; 378(6553):203-6. DOI: 10.1038/378203a0. View

3.
Whitesell L, Sutphin P, Pulcini E, Martinez J, COOK P . The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol. 1998; 18(3):1517-24. PMC: 108866. DOI: 10.1128/MCB.18.3.1517. View

4.
Bey E, Wuerzberger-Davis S, Pink J, Yang C, Araki S, Reinicke K . Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. J Cell Physiol. 2006; 209(3):604-10. DOI: 10.1002/jcp.20783. View

5.
Yam C, Siu W, Arooz T, Chiu C, Lau A, Wang X . MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. 1999; 59(20):5075-8. View